Delaney to head Unichem Pharma’s North American business
Specialty generics maker Unichem Pharmaceuticals has new leadership. The Hasbrouck Heights, N.J.-based company on Thursday named Scott Delaney president and CEO North America.
Delaney, who also joined the company’s board of directors, has nearly a quarter-century of experience in the branded and generic pharmaceutical industries. He was most recently president of Heritage Pharmaceuticals, a division of Emcure Pharmaceuticals. He has experience in such areas of generics management as sales, marketing, contract negotiation and business development, as well as manufacturing and distribution, third-party payer management, product portfolio selection and product lifecycle management.
Delaney’s experience has spanned manufacturers — including Eli Lilly, Johnson & Johnson, Teva and Edenbridge Pharmaceuticals, among others — and time at H-E-B.
“I am honored to accept the role of President and Chief Executive Officer – North America for Unichem at this exciting time for the company,” Delaney said. “[Chairman and managing director Prakesh] Mody and the entire Unichem team have been extremely welcoming to me and my family. They have built a tremendous organization and are very well positioned for the future in the pharmaceutical industry. I look forward to continuing to build on this success while helping to identify new and exciting opportunities that will create additional long-term value for Unichem Laboratories.”
Delaney, who also joined the company’s board of directors, has nearly a quarter-century of experience in the branded and generic pharmaceutical industries. He was most recently president of Heritage Pharmaceuticals, a division of Emcure Pharmaceuticals. He has experience in such areas of generics management as sales, marketing, contract negotiation and business development, as well as manufacturing and distribution, third-party payer management, product portfolio selection and product lifecycle management.
Delaney’s experience has spanned manufacturers — including Eli Lilly, Johnson & Johnson, Teva and Edenbridge Pharmaceuticals, among others — and time at H-E-B.
“I am honored to accept the role of President and Chief Executive Officer – North America for Unichem at this exciting time for the company,” Delaney said. “[Chairman and managing director Prakesh] Mody and the entire Unichem team have been extremely welcoming to me and my family. They have built a tremendous organization and are very well positioned for the future in the pharmaceutical industry. I look forward to continuing to build on this success while helping to identify new and exciting opportunities that will create additional long-term value for Unichem Laboratories.”